Division of Regenerative Medicine, Department of Basic Clinical Science, Tokai University School of Medicine, Kanagawa, Japan.
Diabetes. 2013 Sep;62(9):3207-17. doi: 10.2337/db12-1621. Epub 2013 May 13.
Delayed diabetic wound healing is, in part, the result of inadequate endothelial progenitor cell (EPC) proliferation, mobilization, and trafficking. Recently, we developed a serum-free functional culture system called the quality and quantity culture (QQc) system that enhances the number and vasculogenic potential of EPCs. We hypothesize that QQc restoration of diabetic EPC function will improve wound closure. To test this hypothesis, we measured diabetic c-kit(+)Sca-1(+)lin(-) (KSL) cell activity in vitro as well as the effect of KSL cell-adoptive transfer on the rate of euglycemic wound closure before and after QQc. KSL cells were magnetically sorted from control and streptozotocin-induced type I diabetic C57BL6J bone marrow. Freshly isolated control and diabetic KSL cells were cultured in QQc for 7 days and pre-QQc and post-QQc KSL function testing. The number of KSL cells significantly increased after QQc for both diabetic subjects and controls, and diabetic KSL increased vasculogenic potential above the fresh control KSL level. Similarly, fresh diabetic cells form fewer tubules, but QQc increases diabetic tubule formation to levels greater than that of fresh control cells (P < 0.05). Adoptive transfer of post-QQc diabetic KSL cells significantly enhances wound closure compared with fresh diabetic KSL cells and equaled wound closure of post-QQc control KSL cells. Post-QQc diabetic KSL enhancement of wound closure is mediated, in part, via a vasculogenic mechanism. This study demonstrates that QQc can reverse diabetic EPC dysfunction and achieve control levels of EPC function. Finally, post-QQc diabetic EPC therapy effectively improved euglycemic wound closure and may improve diabetic wound healing.
糖尿病创面愈合延迟的部分原因是内皮祖细胞(EPC)增殖、动员和迁移不足。最近,我们开发了一种无血清功能培养系统,称为质量和数量培养(QQc)系统,该系统可增加 EPC 的数量和血管生成潜能。我们假设 QQc 可恢复糖尿病 EPC 功能,从而改善创面闭合。为了验证这一假设,我们测量了体外糖尿病 c-kit(+)Sca-1(+)lin(-)(KSL)细胞的活性,以及 KSL 细胞过继转移对 QQc 前后糖尿病创面闭合率的影响。KSL 细胞从对照和链脲佐菌素诱导的 1 型糖尿病 C57BL6J 骨髓中通过磁珠分选获得。新鲜分离的对照和糖尿病 KSL 细胞在 QQc 中培养 7 天,并进行预 QQc 和后 QQc KSL 功能测试。无论糖尿病患者还是对照组,经 QQc 处理后 KSL 细胞数量均显著增加,且糖尿病 KSL 细胞的血管生成潜能高于新鲜对照 KSL 细胞。同样,新鲜的糖尿病细胞形成的小管较少,但 QQc 增加了糖尿病小管的形成,使其达到超过新鲜对照细胞的水平(P<0.05)。与新鲜的糖尿病 KSL 细胞相比,过继转移后 QQc 的糖尿病 KSL 细胞显著增强了创面闭合,且与后 QQc 的对照 KSL 细胞的创面闭合相当。后 QQc 糖尿病 KSL 增强创面闭合部分是通过血管生成机制介导的。本研究表明,QQc 可逆转糖尿病 EPC 功能障碍,达到 EPC 功能的对照水平。最后,后 QQc 糖尿病 EPC 治疗可有效改善糖尿病创面的闭合,并可能改善糖尿病创面愈合。